Serum -fetoprotein in hepatoma patients after liver transplantation.
Serum -fetoprotein in hepatoma patients after liver transplantation.
复制标题
肝移植术后肝癌患者血清甲胎蛋白的变化。
DOI：
10.1016/s0016-5085(19)33592-9
复制
发表时间：
1971
期刊：
影响因子：
29.4
通讯作者：
K. Isselbacher
中科院分区：
文献类型：
--
作者：
E. Alpert;T. Starzl;P. Schur;K. Isselbacher
对5例肝癌患者行全肝切除和原位肝移植术后血清甲胎蛋白(α-1-FetProtein，AFP)进行了检测。免疫抑制治疗、排斥反应和感染不会改变血清AFP水平。移植后持续低甲胎蛋白水平提示3例患者存在缓慢生长的残留肿瘤。在1例患者中，在临床证据显示肿瘤快速生长之前，血清AFP水平急剧上升。1例甲胎蛋白消失，9个月后仍无症状，提示肿瘤很少残留或无残留。系列甲胎蛋白水平有助于评估肝癌患者的治疗效果。
α-1-Fetoprotein (AFP) was measured in the sera of 5 hepatoma patients following total hepatectomy and orthotopic liver transplantation. Immunosuppressive therapy, rejection episodes, and infection did not alter the serum level of AFP. Low AFP levels persisting posttransplantation indicated the presence of slow-growing residual tumor in 3 patients. A sharp increase in serum AFP levels preceded clinical evidence of rapid tumor growth in 1 patient. Disappearance of AFP in 1 patient who is still symptom-free after 9 months suggests little or no residual tumor. Serial AFP levels can be helpful in assessing the results of therapeutic attempts in patients with liver carcinoma.